Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.71 |
| ▸ | JAK3 | P52333 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510076 | 0.90 | JAK2 (0.69) | JAK2KCNH2JAK3 | |
| SCHEMBL13270115 | 0.88 | JAK2 (0.78) | JAK2KCNH2JAK3 | |
| SCHEMBL3510635 | 0.87 | JAK2 (0.68) | JAK2KCNH2JAK3 | |
| SCHEMBL3513593 | 0.87 | JAK2 (0.68) | JAK2KCNH2JAK3 | |
| SCHEMBL3511408 | 0.87 | JAK2 (0.80) | JAK2KCNH2JAK3 | |
| SCHEMBL13117308 | 0.87 | JAK2 (0.67) | JAK2KCNH2JAK3 | |
| SCHEMBL3512442 | 0.86 | JAK2 (0.67) | JAK2KCNH2JAK3 | |
| SCHEMBL3509979 | 0.86 | JAK2 (0.76) | JAK2KCNH2JAK3 | |
| SCHEMBL3510210 | 0.86 | JAK2 (0.57) | JAK2KCNH2JAK3 | |
| SCHEMBL3509644 | 0.86 | JAK2 (0.66) | JAK2KCNH2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | claimed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | claimed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-11066393-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200299278-A1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10710985-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3371168-B1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-05-27 | — | — | EP | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| WO-2017076852-A1 | INDOLIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-11 | — | — | WO | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2012049277-A1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-19 | — | — | WO | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226106-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | JAK2 617/4885KCNH2 1774/4885JAK3 3530/4885 |
| US-10710985-B2 | Indolin-2-one derivatives | GRIN2B, GRIN2A, TPH2 | JAK2 1966/4885KCNH2 1223/4885JAK3 1873/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | JAK2 1/4885KCNH2 1655/4885JAK3 2/4885 |
| US-11066393-B2 | Indolin-2-one derivatives | GRIN2B, GRIN2A, TPH2 | JAK2 1966/4885KCNH2 1223/4885JAK3 1873/4885 |
| US-20200299278-A1 | INDOLIN-2-ONE DERIVATIVES | GRIN2B, GRIN2A, TPH2 | JAK2 1966/4885KCNH2 1223/4885JAK3 1873/4885 |
| US-10995091-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | JAK2 617/4885KCNH2 1774/4885JAK3 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.